ClinicalTrialsFinder
RecruitingPhase 1NCT06349837

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Safety and Tolerability of Low Dose Radiotherapy Plus Concurrent Partial Stereotactic Ablative Radiotherapy (Eclipse-RT) and Tislelizumab in Patients With Bulky Tumors

Sponsor

Sichuan University

Enrollment

24 participants

Start Date

Apr 18, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy, and others for people with solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTislelizumab

Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.

RADIATIONLow Dose Radiotherapy

LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.

RADIATIONStereotactic Ablative Radiotherapy

Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.

Locations(1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06349837

Related Trials

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT0493961041 locations

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT064753001 location

Imaging of Solid Tumors Using 18F-TRX

NCT069421041 location

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

NCT075892051 location